News
06-08-2010, 02:40 AM
Abraxis BioScience, Inc. announced today that findings from their phase 3 randomized trial of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) plus carboplatin, showed a statistically significant 31 percent improvement in overall response rate when compared with Taxol (paclitaxel) injection plus carboplatin in the first-line treatment of patients with non-small cell lung cancer.
More... (http://www.news-medical.net/news/20100608/Findings-from-Abraxis-BioSciences-phase-3-ABRAXANE-trial-in-patients-with-NSCLC-presented-at-ASCO.aspx)
More... (http://www.news-medical.net/news/20100608/Findings-from-Abraxis-BioSciences-phase-3-ABRAXANE-trial-in-patients-with-NSCLC-presented-at-ASCO.aspx)